Advertisement Chemically Derived Pharmaceuticals - Pharmaceutical Business review

Advertisement

Pharmaceutical Business review is using cookies

ContinueLearn More
Close
close icon

BioPartners

Developing Biologics, Delivering Patient Care

More info about BioPartners

Chemically Derived Pharmaceuticals

BioPartners

Ribavirin BioPartners

As a standard treatment, Ribavirin is indicated for use in combination with Interferon Alpha to treat chronic Hepatitis C (HCV) infection. Ribavirin is a chemically derived pharmaceutical and belongs to a class of drugs called nucleoside analogues.

Status: Approved by EMA

Ribavirin is a chemically-derived synthetic analogue of guanosine that has a broad spectrum anti-viral effect by inhibiting RNA polymerase of various RNA viruses.

Biopartners has developed a patented, coated tablet formulation of ribavirin, which is a tablet for daily use, solely in combination with interferon alpha for the treatment of chronic, active hepatitis C.

Around 200 million people worldwide are infected with hepatitis C (about 3.3% of the world’s population) and over 80% are chronically infected, with 3-4 million new infections each year.

Quick Contact Chemically Derived Pharmaceuticals